During past 3 decades, nuclear medicine has flourished as vibrant and independent medical specialty in Iran. Since that time, more than 200 nuclear physicians have been trained and now practicing in nearly 158 centers throughout the country. In the same period, Tc-99m generators and variety of cold kits for conventional nuclear medicine were locally produced for the first time. Local production has continued to mature in robust manner while fulfilling international standards. To meet the ever-growing demand at the national level and with international achievements in mind, work for production of other Tc-99m-based peptides such as ubiquicidin, bombesin, octreotide, and more recently a kit formulation for Tc-99m TRODAT-1 for clinical use was introduced. Other than the Tehran Research Reactor, the oldest facility active in production of medical radioisotopes, there is one commercial and three hospitalbased cyclotrons currently operational in the country. I-131 has been one of the oldest radioisotope produced in Iran and traditionally used for treatment of thyrotoxicosis and differentiated thyroid carcinoma. Since 2009, 131 I-meta-iodobenzylguanidine has been locally available for diagnostic applications. Gallium-67 citrate, thallium-201 thallous chloride, and Indium-111 in the form of DTPA and Oxine are among the early cyclotron-produced tracers available in Iran for about 2 decades. Rb-81/Kr-81m generator has been available for pulmonary ventilation studies since 1996. Experimental production of PET radiopharmaceuticals began in 1998. This work has culminated with development and optimization of the highscale production line of 18 F-FDG shortly after installation of PET/CT scanner in 2012. In the field of therapy, other than the use of old timers such as I-131 and different forms of P-32, there has been quite a significant advancement in production and application of therapeutic radiopharmaceuticals in recent years. Application of 131 I-meta-iodobenzylguanidine for treatment of neuroblastoma, pheochromocytoma, and other neuroendocrine tumors has been steadily increasing in major academic university hospitals. Also Re-sulfur colloid, and 188/186 Re-HEDP have been locally developed and now routinely available for bone pain palliation and radiosynovectomy. Cu-64 has been available to the nuclear medicine community for some time. With recent reports in diagnostic and therapeutic applications of this agent especially in the field of oncology, we anticipate an expansion in production and availability. The initiation of the production line for gallium-68 generator is one of the latest exciting developments. We are proud that Iran would be joining the club of few nations with production lines for this type of generator. There are also quite a number of SPECT and PET tracers at research and preclinical stage of development preliminarily introduced for possible future clinical applications. Availability of fluorine-18 tracers and gallium-68 generators would no doubt allow rapid dissemination of PET/CT practices in various parts of our large country even far from a cyclotron facility. Also, local production and availability of therapeutic radiopharmaceuticals 340 http://dx
I-meta-iodobenzylguanidine has been locally available for diagnostic applications. Gallium-67 citrate, thallium-201 thallous chloride, and Indium-111 in the form of DTPA and Oxine are among the early cyclotron-produced tracers available in Iran for about 2 decades. Rb-81/Kr-81m generator has been available for pulmonary ventilation studies since 1996. Experimental production of PET radiopharmaceuticals began in 1998. This work has culminated with development and optimization of the highscale production line of 18 F-FDG shortly after installation of PET/CT scanner in 2012. In the field of therapy, other than the use of old timers such as I-131 and different forms of P-32, there has been quite a significant advancement in production and application of therapeutic radiopharmaceuticals in recent years. Application of 131 I-meta-iodobenzylguanidine for treatment of neuroblastoma, pheochromocytoma, and other neuroendocrine tumors has been steadily increasing in major academic university hospitals. Also 153 Sm-EDTMP, 177 Lu-EDTMP, 90 Y-citrate, 90 Y-hydroxyapatite colloid, 188/186 Re-sulfur colloid, and 188/186 Re-HEDP have been locally developed and now routinely available for bone pain palliation and radiosynovectomy. Cu-64 has been available to the nuclear medicine community for some time. With recent reports in diagnostic and therapeutic applications of this agent especially in the field of oncology, we anticipate an expansion in production and availability. The initiation of the production line for gallium-68 generator is one of the latest exciting developments. We are proud that Iran would be joining the club of few nations with production lines for this type of generator. There are also quite a number of SPECT and PET tracers at research and preclinical stage of development preliminarily introduced for possible future clinical applications. Availability of fluorine-18 tracers and gallium-68 generators would no doubt allow rapid dissemination of PET/CT practices in various parts of our large country even far from a cyclotron facility. Also, local production and availability of therapeutic radiopharmaceuticals Introduction I n Iran, Nuclear Medicine began with 24-hour urinary radioactive iodine measurement more than half a century ago and continued mainly in the area of thyroid hormone measurements and other endocrine-related assays. Research Center for Nuclear Medicine (RCNM) in Tehran University of Medical Sciences is the first nuclear medicine center in the country founded in 1967. This center has been active in all areas of nuclear medicine and recognized as a center of excellence. The RCNM is one of the busiest centers in the region providing broad scope of nuclear medicine services with particular emphasis in the management of patients with thyroid cancer. The Iranian Journal of Nuclear Medicine has been published by RCNM since 1993. The quality and volume of work that has been published in recent years symbolizes the robust academic interests in the Iranian nuclear medicine and radiopharmacy community.
The nation's first residency program was established in 1983 at the RCNM. Since that time, more than 200 nuclear physicians have been trained and now practicing in nearly 158 centers throughout the country (Fig. 1) . The Iranian Society of Nuclear Medicine was established in 1973.
Like other parts of the world, advances in nuclear medicine have occurred in our country in all three main aspects of the field including imaging, in vitro and laboratory studies, as well as therapy. At the present time, there are more than 200 SPECT, 5 SPECT/CT, and 3 PET/CT facilities operating across in the country. Ambulatory treatment is a common practice in all nuclear medicine centers; however, there are 10 hospitals with dedicated wards for inpatient treatment especially for thyroid cancer, bone pain palliation, radiosynovectomy (RSV), 131 I-meta-iodobenzylguanidine (MIBG) therapy, etc. With a population of 78.1 million as of 2014, it is no surprise that over 360,000 diagnostic and therapeutic nuclear medicine procedures have been performed throughout the country. These include approximately 4000 thyroid cancer and 8000 hyperthyroid treatments.
The first center for nuclear technology in Iran, the Tehran Nuclear Research Center, was established followed by an agreement with Autorité des Marchés Financiers, an American company, for construction of Tehran Research Reactor (TRR) in 1960. Since then, especially during last two decades, great deal was invested in research and development of radiopharmaceuticals, and currently the country has one of the best production and distribution facilities in the Middle East region.
The radionuclide production facility includes a 5 MW pool type reactor located in Tehran and an IBA cyclotron (Cyclon C-30) located in Karaj operated by Atomic Energy Organization of Iran, and there are also four hospital-based cyclotrons in the country.
Diagnostic Radiopharmaceuticals

Single Photon Emission Computed Tomography Agents
Tc-99m Generators Tc-99m radiopharmaceuticals are most applied agents in nuclear medicine for diagnostic imaging. This radionuclide is used in over 80% of all diagnostic procedures. Radionuclide generators are the major point of development and availability of these tracers.
The first assembling line for 99 Mo/ Gel-Moly Generator. Owing to limitations in importing Mo-99 since 2006 and existing or increasing demand for Tc-99m radiopharmaceuticals in the country, the development of gel generators was completed in 2007, and this low specific activity generator found its way into clinic at the time covering the national need under the brand name JABERTEC. The generator consists of an extra guard column to remove possible metal impurities interfering the kit radiolabeling yielding a specific activity of 1.85 GBq/mL. These generators have been launched at 100, 200, 300, and 400 mCi of activities at national level.
Fission-Moly Generators. To meet the increasing demand for 99 Mo/ 99m Tc generators especially in major cities in the country, the need for high specific activity was recognized, and in 2012, fission-moly-based generators with the brand name of PARSTEC II with specific activity of up to 18.5 GBq/mL were launched and are available at 400, 600, 800, and 1000 mCi of activity at national level. Figure 2 shows the number of 99 
Mo/ 99m
Tc generators distributed in 2014 in the country. Figure 3 shows the increasing demand of 99m Tc usage (activity) by nuclear medicine centers from 2008-2014.
Tc-99m Cold Kits
Since early 1990s, the kit products are produced and formulated in the country at authorized manufacturing facilities according to GMP requirements. Some of the available 99m Tc-radiopharmaceutical kits distributed nationwide at Tc-Bombesin and dynamic and static imaging with SPECT acquisition and histopathological examination as gold standard, they yielded a high sensitivity (100%) and NPV (100%) for detecting malignant breast lesions; however, specificity (66.1%) and PPV (63%) for differentiating malignant breast abnormalities from benign lesions were relatively low. elevated ACTH and serum cortisol levels with bilateral adrenal hyperplasia seen on spiral abdominal CT scan and normal brain MRI. Whole-body 99m Tc-labeled octreotide acetate scintigraphy was performed to check for the presence of an ectopic adrenocorticotropic hormone-producing tumor. The scan results showed a small focal increase uptake in the lower lobe of the right lung, just above diaphragm. A spiral chest CT also revealed a small nonspecific lesion in the same region. Pathology from transthoracic biopsy specimen confirmed the diagnosis of anadrenocorticotropic hormone-producing type of carcinoid tumor. After surgical removal, the patient's symptoms resolved and significant clinical improvement was achieved. Pirayesh Tc-TRODAT-1 SPECT in the diagnosis of Parkinson disease vs other progressive movement disorders in 75 patients (29 PD, 6 possible PD, 22 Essential Tremor, and 18 Parkinson Syndrome). Dual-head SPECT-CT imaging was performed to assess basal ganglia activity after IV injection of Tc-Trodat-1, which after adding indices of asymmetry for basal ganglia and unevenness of uptake in putaman or caudate lobe or both contralateral to the dominant side of the patient's symptom, resulted in sensitivity, specificity, and PPV of 80%, 83.3%, and 82.6%, respectively. They concluded that 99m Tc-TRODAT-1 scan, both based on scan pattern and quantitative indices, is an appropriate method for differentiating PD or Parkinson syndrome from essential tremor.
I-131 (Diagnostic)
Sodium iodide I-131 is one of the oldest radioisotopes used for thyroid evaluation. I-131 has been produced at TRR using an (n,p) reaction on Xe-124-enriched gas. The radiopharmaceutical has been available in the country for long time.
I-131 MIBG (Diagnostic)
The MIBG is an analogue of the adrenergic neuron blocking labeled with I-131 as a valuable radiopharmaceutical widely used in nuclear medicine for both diagnostic imaging and targeted radiotherapy of neural crest derived tumors, such as neuroblastoma and pheochromocytoma. The radiopharmaceutical production at large scales was developed in 2009 using a Cu (I)-mediated iodination in the country.
29
Gallium-67 Citrate Production. Gallium-67 (Ga-67) is a bioisoester of ferric iron with physical half-life of 3.3 days (78 hours) and biologic halflife of 2-3 weeks that binds to serum via transferrin, haptoglobin, albumin, and globulins. Gallium attaches to tissues mediated by lactoferrin, as well as lymphocytes and macrophages. Apart from its application in tumor imaging, Ga67citrate remains a major tool for the detection of inflammation and infections. 30 67 Ga is locally produced in a medium-energy cyclotron, Cyclone 30, using 68 Zn(p,2n) 67 Ga followed by target dissolution and ion chromatography purification and formulation using citrate salt and is shipped to various nuclear medicine centers in the country for more than 20 years.
31
Local Clinical Evaluations. Sadeghi et al 32 compared sensitivity of planar and SPECT gallium scintigraphy for evaluation of recurrent lymphoma. A total of 129 patients with suspicious recurrent lymphoma of the thorax were included into the study. All patients received 10 mCi 67 Ga citrate intravenously. Overall, 24 and 48 hours postinjection, whole-body and thoracic SPECT imaging were performed. The final diagnosis of recurrence was achieved by combination of clinical and imaging findings or pathologic examination whenever possible. The sensitivity of planar and SPECT imaging for diagnosis of recurrent lymphoma was 63% ([52%-73%] with 95% CI) and 87% ([79%-94%] with 95% CI), respectively. In their study, 20 patients with the final diagnosis of lymphoma recurrence in the thoracic area had negative planar despite positive SPECT imaging. This showed an increase of 24% in sensitivity of the scan (from 63%-87%) by adding SPECT imaging to the procedure. They recommended integrating SPECT modality into all gallium scintigraphy for lymphoma recurrence. Tl is produced in a medium-energy cyclotron, Cyclone 30, using 203 Tl(p,n) 203 Pb- 201 Tl followed by target dissolution and two-step ion chromatography purification and formulation and delivered to various nuclear medicine centers in the country for more than 20 years.
33,34
Local Clinical Evaluations. Mirfallah et al 35 conducted a study for preoperative assessment of meningioma aggressiveness by Thallium-201 brain SPECT. A total of 30 lesions in 28 patients were evaluated in this study. Early (20 minutes) and late (3 hours) brain SPECT after IV injection of 3 mCi of 201 Tl were performed and early uptake ratio (EUR) ¼ Average count of lesion/average count of contralateral brain in early image, late uptake ratio (LUR) ¼ Average count of lesion/average count of contralateral brain in late image and retention index ¼ LUR/EUR were calculated. Performing receiver operating characteristic curve analysis and according to coordinates of curves, in retention index 40.75 and LUR 4 4, the sensitivity and specificity of 201 Tl Brain SPECT were 80% to differentiate malignant from benign meningioma. Fallahi et al 36 reported use of 201 Tl SPECT imaging in three cases of suspicious recurrent colorectal cancer. Based on pathologic examination and patients' follow-up, 201 Tl scintigraphy truly shows recurrence in two patients and truly reveals lack of recurrence in one patient.
Indium-111 Oxine
Production. Indium-111 (In-111, half-life: 67 hours) is a suitable SPECT radionuclide and is produced by a mediumsize cyclotron in Karaj, Iran, using the 112 Cd(p,2n) 111 In reaction followed by target dissolution and ion chromatography purification and formulation.
37,38 The radionuclide as well as In-111 oxine is not produced on a regular basis but according to the requests provided by the nuclear medicine centers. In-oxine labeling on cellular viability and counts, all samples were examined immediately after labeling (2 hours) as well as 24, 48 hours, and 5, 7, and 14 days postlabeling. They found a negative correlation between radiotracer dosage and viability during the 2-week period of follow-up and concluded that cytotoxic effects of 111 In on human stem cells is a time-dependent phenomenon, and hence assessment of the stem cell viability immediately after labeling (which is frequently made in clinical trials) is unable to detect longterm adverse effects of this radiopharmaceutical on the integrity of stem cells. Even low doses of 111 In-oxine are accompanied by significant cell loss in a 2-week period. Although it has been confirmed that nuclear medicine techniques are the most sensitive methods for stem cell tracking, they recommend that the application of this tracking technique should be treated with great reserve, and if necessary, as little of 111 In-oxine as possible should be added to the cells (or only a limited portion of the cells should be labeled) to minimize cell death.
In-111 DTPA In-111 DTPA, also known as pentetate Indium disodium In-111, is recommended for use in radionuclide cisternography after intrathecal administration; the production procedure is quite simple, however, and should be performed under very sterile conditions. 40 Rb-81/Kr-81m Generator The Rb-81/Kr-81m generator is a valuable radionuclide generator for the diagnosis of lung diseases and has been prepared since 1996 in the country using irradiation of natural krypton gas in a medium-size cyclotron and is available on a weekly basis. 41 The mother radionuclide (rubidium-81) is immobilized on a membrane, through which the daughter radionuclide (krypton-81m) is eluted with the passing of air. Krypton-81m is ideally suited for lung ventilation studies. It has very short half-life and results in a low radiation burden for the patient. With gamma energy higher than that of 99m Tc, it enables lung ventilation studies to be performed immediately after a perfusion study of the pulmonary vascular bed.
PET Radiopharmaceuticals
In mid-80s the production routes for the most widely used PET tracer, FDG, was introduced and in less than a decade many other fluorine-18 [ minutes, steric similarity to hydrogen atom). The research and development of PET radiopharmaceuticals initiated in 1996 in Iran based on some postgraduate projects is 42 followed by experimental production and quality control of NaF, FDG, and other research tracers. At present, FDG is the major PET radiotracer in the country similar to many other parts of the world.
F-18 NaF
Sodium fluoride (Na 18 F) is the simplest PET radiopharmaceutical product. The F-18 is routinely produced in three cyclotrons in the country based on the bombardment of enriched water (H 2 18 O) with accelerated protons. 43 F-18 FDG F-18 FDG is an analogue of glucose that contains the radionuclide F-18. As a glucose analog, F-18 FDG is transported into most of cells including brain cells, myocytes, as well as many malignant cells over-expressing glucose transporter and can enter metabolic glucose pathways, after phosphorylation by hexokinase. The major production route in the country similar to rest of the world is based on cassette-based modules initially using catalyst-based nucleophilic substitution reaction. The first experimental production of FDG in the country was performed in 1998 for initial production and quality control setups 44 based on a PhD thesis, followed by intensive research and development on optimizations in production and quality control practice. 45 The first local clinical evaluations using FDG, however, were initiated in 2005 for central nervous system studies on patients with chronic tinnitus. 46 However, in 2012, after installation of the PET/CT machines in the country, high-scale production and application of the tracer has begun.
Therapeutic Radiopharmaceuticals
I-131 Oral Solution
Production Sodium Iodide I-131 therapeutic solutions is indicated for the treatment of hyperthyroidism and differentiated thyroid cancers (DTC). I-131 is produced by the irradiation of Xe-124 in the TRR. The production is straightforward and based on rapid chemistry with the recovery of xenon gas yielding a high specific activity. Figure 5 shows the amount of I-131 activity consumption in the country as well as RCNM in 2014.
Local Clinical Evaluations
Fallahi et al 47 compared low vs high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with DTC. In total, 341 patients with thyroidectomy were randomly allocated to the high-dose group, 3700 MBq (170 patients), vs the low-dose group, 1110 MBq (171 patients), for radioiodine ablation therapy in a double-blind randomized clinical trial. The response to treatment was defined as successful or unsuccessful according to posttherapy ultrasonography of the neck, serum thyroglobulin (Tg), anti-Tg, and functioning residual tissue after 6-month and 12-month intervals. The major criteria of successful ablation were Tg o 2 ng/mL, anti-Tg o 100 IU/mL, and absent remnant in the off levothyroxine state. Additional radioiodine doses were administered in cases showing no significant response to the first therapy. Finally, the initial outcome, the total hospitalization time, and the cumulative I-131 doses during the 12-month course of the study were compared between the subgroups. They found that rate of initial successful ablation was 51.6% in all patients, 39.2% in the low-dose group, and 64.1% in the high-dose group. The corresponding success rates at the end of the 12-month follow-up without additional treatment were 55.1%, 41.5%, and 68.8%, respectively. The relative risk of unsuccessful ablation for the low-dose vs the high-dose group was 1.695 [95% CI: 1.34-2.14]. In the low-dose group, more patients needed a second dose of I-131, resulting in a higher cumulative activity (median: 4810 vs 3700 MBq, P o 0.0001) and more inpatient time (median: 4 vs 3 days) in comparison with the high-dose group. They concluded that the higher dose of I-131 (3700 MBq) resulted in successful ablation more often than the low dose (1110 MBq).
Fard-Esfahani et al 48 evaluated nasolacrimal duct obstruction as a complication ofiodine-131 therapy in 81 patients with thyroid cancer. A total of 17 age-matched sex-matched individuals were selected as control group. Nasolacrimal duct obstruction (NLDO) was observed in 18% of the exposed eyes and 9% of the control eyes. NLDO was evident in 27.4% of the eyes of the patients treated with11.1 GBq I-131 or more. They concluded that NLDO may be considered as a side effect of I-131 therapy, especially with a cumulative dose of 11.1 GBq or more.
Fallahi et al 49 evaluated protective role of Vitamin E against I-131 radiation damage to salivary glands in patients with thyroid cancer. By comparing results of 99m Tc-pertechnetate salivary gland scintigraphy in control group and in the group receiving 800 IU/day Vitamin E for a duration of 1 week before to 4 weeks after I-131 therapy, they concluded that Vitamin E consumption may be associated with a significant protective effect against radiation-induced dysfunction in salivary glands following single-dose 131 I therapy in patients with DTC. Fard-Esfahani et al 50 reviewed early and late adverse effects of radioactive iodine-131 treatment for DTC.
Zakavi et al 51 compared four different protocols (low and high as well as fixed and calculated doses) of I-131 therapy for treating single toxic thyroid nodule and concluded that calculated high-dose protocol is preferable in old patients with toxic adenoma, whereas calculated low-dose protocol is more appropriate in young patients.
Esfahani et al 52 evaluated gonadal functions in 159 females and 87 males treated for differentiated thyroid cancer with I-131. In male patients, the average serum level of folliclestimulating hormone 2-6 months after each course of treatment was significantly higher than before treatment, revealing significant correlation with the cumulative dose of 131 I received. Reduced sperm count was found in 35.8% of the male patients. In 36.8% of these patients (13.2% of the total), this finding was persistent during the follow-up period. In females, they found no significant correlation between gonadal-hypophyseal hormones and treatment with 131 I, and there were no signs and symptoms of sexual dysfunction. Infertility or abortion was not noticed in any patients. They concluded that although female gonads are resistant to radioiodine treatment for thyroid cancer, in males this treatment may lead to impairment of the gonadal function, which is transient most of the times. Spermatogenesis is especially sensitive to the radiation effect of 131 I treatment and this effect is related to the cumulative radioiodine dose.
Fallahi et al 53 evaluated incidence of second primary malignancies (SPMs) during a long-term surveillance of 973 patients with DTC in relation to radioiodine treatment during a median of 6 years follow-up. A total of 11 patients from 7370 person-years at risk developed an SPM. The standardized rate ratio of nonthyroid malignancy was 0.81 (95% CI: 0.57-1.04) for the studied patients relative to the general population. After adjusting for several variables, the cumulative dose of I-131 more than 40 GBq (1.08 Ci) was the sole factor associated with increased odds of SPM. They concluded that although the overall rate of SPMs was not significantly increased after a 
I-131 MIBG Therapeutic
Production Using high specific activity I-131, the production and quality control of MIBG was initiated in 2008. The production reaction was based on copper (I)-assisted radioiodine exchange at high temperature. At optimized conditions the best radiochemical yield for therapeutic applications was obtained.
Local Clinical Evaluations I-131 MIBG can be used to treat neuroblastoma, paraganglioma, ganglioneuroblastoma, and pheochromocytoma, cancerous tumors that arise from neural crest. At the moment the agent is prepared and sent based on standing orders to the centers. Hamidieh et al 57 ). Patients received 13-cis retinoic acid after ASCT. Three-year follow-up lead to the 3-year overall survival rates of 66 Ϯ 21% and 53 Ϯ 20% in MIBG-avid and MIBG-non-avid subgroups, respectively. The 3-year event-free survival rates were 66 Ϯ 21% and 47 Ϯ 19% in MIBG-avid and MIBG-non-avid subgroups, respectively. They suggest that pre-ASCT diagnostic MIBG scintigraphy has a role in treatment decision-making in neuroblastoma. MIBGavid subgroup may benefit from the combination of therapeutic MIBG and high dose of chemotherapy.
Sm-153 EDTMP Production
153
Sm-ethylenediamine tetramethylene phosphonic acid ( 153 Sm-EDTMP) is a currently used agent for effective palliative treatment of skeletal metastases. Samarium-153 has favorable radiation characteristics, such as the medium-energy beta particle emissions (E max ¼ 810 keV) that is desirable for treatment, the medium-energy gamma photon (103 keV) that is suitable for imaging, and the short half-life (46.3 hours). The total synthesis and quality control as well as preclinical studies of this agent are carried out and reported in 2009. 58 
Local Clinical Evaluations
Ayati et al 59 evaluated treatment efficacy of 153 Sm-EDTMP in 28 patients with painful bone metastases from different cancers. A total of 1 mCi/kg 153 Sm-EDTMP was injected intravenously and whole-body imaging was performed 3-18 hours postinjection. Pain relief began 2-16 days postinjection. Mean duration of pain palliation was about 15 weeks. Complete and partial response was observed in 64.3% and 21.4% of patients, respectively, leading to an overall 85.7% response to therapy with no significant hematological complications. Authors concluded that 153 Sm-EDTMP is a safe and effective agent for bone palliation treatment. Beiki et al 60 also assessed effectiveness and complications of 153 Sm-EDTMP in palliative therapy of 16 patients with diffuse skeletal metastases from different cancers. Significant response to therapy was observed in 68.7% of patients by the second week and in 75% of the patients by the eighth week after IV injection of 1.5 mCi/kg 153 Sm-EDTMP, without significant difference between cancer types, age, or sex. Hematologic toxicity was mild to moderate with no lifethreatening complications. The agent is now available in the country per request.
Lu-177 EDTMP Production
Owing to the suitable decay characteristics (t 1/2 ¼ 6.73 days, E β max ¼ 497 keV, Eγ ¼ 112 keV [6.4%], 208 keV [11%]) as well as the feasibility of large-scale production in adequate specific activity and radionuclide purity by using a moderate flux reactor, 177 Lu deemed a promising radionuclide in the development of 177 Lu-EDTMP complex. Total synthesis and production of 177 Lu-EDTMP were performed in the country and preclinical studies were reported in 2012. 61 Alavi et al  62 evaluated the role of   177 Lu-EDTMP in 30 eligible patients with different cancer types for metastatic bone pain palliation therapy. 62 After IV injection of 29.6 MBq/kg 177 Lu-EDTMP, whole-body scans were performed 24 hours, 72 hours, and also 7 days postinjection. Pain relief began 2.53 Ϯ 2.08 weeks after the injection and the response lasted for 4.38 Ϯ 3.34 weeks. Among the 30 patients treated with 177 Lu-EDTMP, 53% showed complete palliative pain response, 30% revealed partial response, and 17% showed no response to treatment. Total response to treatment was achieved in 83% of patients. The agent is now available in the country per request.
Local Clinical Evaluation
Y-90 Citrate Colloid and Y-90 Hydroxyapatite Colloid
The RSV has been applied as an effective treatment to the patients with resistant synovitis for more than P having specific activity of 200 TBq(5500 Ci)/mmole. P-32 sodium phosphate is indicated for the treatment of hematological diseases. It may also be used in palliative treatment of selected patients with skeletal metastases.
P-32 Colloidal Chromic Phosphate
Production 32 P chromic phosphate is supplied as a sterile, nonpyrogenic aqueous solution. It contains 30% dextrose solution, 1 mg sodium acetate, and 2% benzyl alcohol added as a preservative. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.
Local Clinical Evaluations
32
P chromic phosphate colloid is indicated for intracavitary instillation for the treatment of peritoneal or pleural effusions caused by metastatic disease, and may be injected interstitially for the treatment of cancer. It is also used in patients with hemophilia for intra-articular injections. Mortazavi et al 65 used 32 P chromic phosphate RSV in treatment of chronic hemophilicsynovitis. A total of 46 patients with hereditary bleeding disorders and chronic synovitis associated with recurrent hemarthrosis were followed for an average of 31 months. In latest follow-up, 77% of patients reported at least a 50% decrease in bleeding frequency after treatment. The need for antihemophilic factor consumption also dropped to approximately 74% after RSV. The range of motion remained stable or improved in most of the cases.
Shahzadi et al 66 used 32 P chromic phosphate for intracavity irradiation of cystic craniopharyngiomas in 22 patients. Overall (complete and partial) response rate was 73%. Follow-up of patients revealed mean Ϯ SD survival after intracavitary irradiation to be 25.4 Ϯ 6.8 (95% CI: 12.0-38.7) months. They suggest that intracavitary irradiation with 32 P chromic phosphate is highly effective in the treatment of cystic craniopharyngiomas.
Re-188 Sulfur Colloid
Rhenium-188 can be produced with relatively high specific activity by direct production in a nuclear reactor by irradiation of enriched rhenium-187; however, it could be available in W-188/Re-188 generator form for easy clinical use. The availability of Re-188 on demand from this high-performance generator provides great versatility for development of a range of Re-188-labeled therapeutic agents, and the generators have a long useful shelf-life of 46 months. This radionuclide is vastly used in therapeutic studies such as RSV and bone pain palliation therapy. Rhenium-188 sulfur colloid has been produced by reduction of sodium thiosulfate in the presence of perrhenate 67 and was introduced commercially in the country.
Re-186 HEDP
186
Re is a beta and gamma emitter that is used in metabolic radiotherapy and radio immunotherapy. The properties of this radionuclide (t 1/2 ¼ 90.64 hours, E Maxβ ¼ 1.1 MeV, Eγ ¼ 13 keV) after labeling with hydroxyethylidene diphosphonate (HEDP) make it a useful radioisotope for the bone pain palliation therapy. The radionuclide is prepared in TRR by neutron activation. The Re-186 HEDP is now available commercially in the country. Re generator. The radiopharmaceutical is now available commercially in the country. 69 
Agents at Research and Development Level
Apart from the existing radiopharmaceuticals in the country, active research for developing new tracers has been conducted in the country in the last two decades. Many of these studies are based on global new trends and ongoing research in the field of the radiopharmacy leading to quite a number of preclinical studies that are already reported and published.
SPECT Tracers
Technetium-99m Tracers Various researches for production as well as development of new tracers have been conducted in the country during last two decades. Some of these activities were focused on the production of Tc-99m by accelerators, 70, 71 but many works were focused on the development of 99m Tc-radiotracers. Some of these compounds are candidate for clinical evaluation in near future. In Table 1, examples of these   99m Tc-based traces are demonstrated.
Indium-111
During recent years, the main focus has been the development of PET and Tc-99m tracers; however, various In-111-based compounds for possible future use has been produced in our laboratory. A list of these 111 In-radiotracers is shown in Table 2 .
Galllium-67 Tracers
The long half-life and dosimetric issues for developing new tracers based on Ga-67 has been of interest in the radiopharmaceutical research. As a Ga-68 surrogate, lots of research work has been focused on Ga-67 compounds especially for optimization of peptide radiochemistry. 99 A list of various 67 Ga-tracers is presented in Table 3 .
Cobalt-57
Co-57 is an interesting radionuclide formerly used in schilling test, but there has been limited interest for routine use of this radioisotope despite the initiation of a program by International Atomic Energy Agency. 124 However, the radionuclide was successfully prepared, and some interesting tracers were developed based on the radionuclide by our group.
125
191Os/191mIr Generator Iridium-191m (191mIr, t 1/2 ¼ 4.96 seconds), an ultra-shortlived tracer showed to be suitable for gamma imaging available as 191Os/191mIr generator with a low Os-191 breakthrough used in the blood flow studies in the carotid and kidney arteries. The production and quality control of the generator have been reported by research groups. In feasibility study, the production of the Os-191 in TRR as well as appropriate quality control and preclinical studies were conducted. 126 Some tracer development based on in vivo 191Os/191mIr generator for tumor imaging has also been performed in our laboratory.
127,128
Selenium-75 Selenium-75, a gamma-emitting isotope of selenium, is formerly used in labeling various compounds for SPECT imaging, including [ 75 Se]selenomethionine; however, the decay characteristics of selenium-75 are not ideal because of the high radiation dose delivered to the patient. It is now been mostly used in the production of standard sources for gamma camera calibration. The production and quality control of the radionuclide has been performed in 2004 in the country and is now been used in preparing seed sources. 129 
PET Tracers at the Research Level
Ga-68 Generators and Tracers Considering the intriguing physical properties and availability of gallium-68 (t 1/2 ¼ 67.71 minutes), this isotope has become an interesting nuclide for developing new PET tracers. Owing to the availability and commercialization of a new 50 mCi 68 -Ge/ 68 Ga generator in the country based on a SnO 2 solid phase, the development of various tracers has become possible. 130 Ge-68 as the mother radionuclide is produced using 22 MeV proton irradiation of metallic melted gallium powder in niobium capsules in a 30 MeV cyclotron, located in Karaj, Iran. Preclinical studies of many radiotracers based on this generator have been completed, and the generator and technology of production as well as quality control of products are ready for delivery to nuclear medicine centers. Table 4 demonstrates the status of some of recently developed tracers based on this generator in the country.
Copper-64 tracers
Copper-64 has several unique attributes that make it a multipurpose radionuclide with many potential applications. It has a complex decay scheme, with electron capture, beta-emission, and positron emission branches, and it may be described as the archetypal "theranostic" radionuclide, producing excellent PET molecular imaging at low administered doses without major dosimetry or radiobiological concerns, and having potential for radionuclide therapy at high doses with radionuclide distribution and accurate dosimetry possible using PET imaging during therapy. 139 The most important production routes are via 64 Ni (p,n) and 68 Zn(p,αn) routes in small or medium-size cyclotrons or both. Owing to suitable half-life (12.7 hours), it can be used in the development of small size to large-size targeting molecules such as thiosemicarbazones, peptides, and also full size monoclonal antibodies. Table 5 demonstrates the status of some of recently developed tracers based on the copper-64 radionuclide in the country with completed preclinical data.
Other PET Tracers and Radionuclides at the Preclinical Level Copper 61 was produced using a nonexpensive method in the country for the first time and reported in the literature leading to an interesting surrogate for optimization studies for copper radiopharmaceuticals, 147 also production of Ga-66 for the first time at the medium-size cyclotron using readily available, nonexpensive 148 Table 6 shows a list of other PET tracer studied by our group with completed preclinical studies. In Tables 6 and 7 , the status of other PET radionuclides products with completed preclinical studies as well as for possible future applications is shown.
Therapeutic Agents at the Research Level
There are various therapeutic radiopharmaceuticals already available in clinical use in our country. However, the research and development is ongoing for developments of new radiopharmaceuticals. Owing to toxicity, radiation risks, and ethical considerations for therapeutic applications of radiopharmaceuticals, many restrictions and detailed issues, however, need to be taken into consideration. Table 8 shows list of some newly introduced therapeutic radiopharmaceuticals reached to preclinical levels.
Other Radionuclides
Many other radioisotopes have been prepared and formulated for the basic research in biology as well as environmental studies in the past two decades which have been well documented in the literature; however, the application and demand for these radionuclides is limited to local studies and small research projects. Table 9 demonstrates a list of these products. 
Future Trends and Conclusion
In view of initiation of PET/CT projects in past 3 years in our country and governmental policy for installation of new machines especially in major cities and university hospitals, it is expected that Iran would be one of the rapidly increasing markets in the area of PET radiopharmaceuticals and practice. Meanwhile, the presence of more than 158 active nuclear medicine centers and rich human resources at the level of nuclear medicine physicians, radiopharmacists, physicist, technologist, and other related specialties in the country would provide a sustainable infrastructure and capacity for advancement in basic and clinical nuclear medicine sciences and services. Availability of F-18 tracers and recently locally produced Ga-68 generators would no doubt allow rapid dissemination of PET/CT practices in various parts of our large country even far from a cyclotron facility. Also, local production and availability of therapeutic radiopharmaceuticals is going to open exciting horizons in the field of nuclear medicine therapy. Given the available local infrastructure of SPECT imaging and rapidly growing population, the production of Tc-99m generators and cold kit would continue to flourish in Iran. 
